Esketamine Prevents Postpartum Depression: Meta-Analysis

Most research on ketamine and depression focuses on treatment: helping people who already have the condition. A 2025 updated systematic review and meta-analysis published in BMC Pregnancy and Childbirth examined a different question entirely: can esketamine administered during cesarean section prevent postpartum depression from developing in the first place?

For information on treating existing postpartum depression with ketamine, see our pages on ketamine for postpartum depression and our earlier coverage of ketamine and PPD treatment. This post focuses specifically on the prevention data using perioperative esketamine.

The Meta-Analysis

The BMC review systematically collected and analyzed randomized controlled trials that administered esketamine (the S-enantiomer of ketamine) to women undergoing cesarean section and then tracked postpartum depression outcomes. Esketamine was given intravenously during the perioperative period, either as part of the anesthetic protocol or as a supplemental infusion.

The authors pooled data across multiple trials to assess:

• Incidence of postpartum depression at defined follow-up intervals
• Severity of depressive symptoms in those who did develop PPD
• Adverse effects on mother and infant
• Timing and duration of the preventive effect

Key Findings

Significant Reduction in PPD Incidence

The meta-analysis found that women who received perioperative esketamine had a significantly lower incidence of postpartum depression compared to those who received standard anesthesia without esketamine. The reduction was clinically meaningful, not a marginal statistical effect.

The preventive effect was observed across multiple follow-up timepoints, from the early postpartum days through several weeks post-delivery, suggesting that a single perioperative dose can influence mood trajectory for an extended period.

Lower Depression Severity Scores

Among women who did develop depressive symptoms despite receiving esketamine, the severity of those symptoms was generally lower than in the control group. This suggests that even when esketamine does not fully prevent PPD, it may attenuate the condition's severity.

Favorable Safety Profile

The safety data was reassuring for both mothers and infants:

• Maternal side effects were consistent with those expected from esketamine at the doses used: mild dissociation, dizziness, and nausea, all transient and generally well-tolerated in the perioperative context.
• Neonatal outcomes (Apgar scores, need for resuscitation, NICU admission) were not adversely affected by maternal esketamine administration.
• Breastfeeding was not significantly disrupted, though monitoring protocols varied across studies.

Why Prevention Matters

Postpartum depression affects approximately 10% to 15% of new mothers, with higher rates among women undergoing cesarean section. The condition carries profound consequences:

• Impaired maternal-infant bonding
• Disrupted breastfeeding
• Developmental effects on the infant
• Increased risk of chronic depression
• In severe cases, risk of self-harm or harm to the infant

Current prevention strategies are limited. While screening and early intervention are recommended, there is no widely adopted pharmacological prevention protocol. Most women are not identified as at risk until they are already symptomatic.

The idea of administering a single dose of esketamine during a procedure that is already happening (cesarean section under anesthesia) is appealing because it requires no additional appointments, no ongoing medication adherence, and minimal disruption to the birth experience.

The Mechanism

The proposed mechanism for esketamine's preventive effect draws on the same neurobiology that underlies its antidepressant properties:

Neuroplastic priming: Esketamine's BDNF-mediated neuroplastic effects may strengthen prefrontal cortex functioning during a period of extreme hormonal and psychosocial stress, making the brain more resilient to the mood disruptions that trigger PPD.

Anti-inflammatory effects: The peripartum period involves significant inflammatory changes. Esketamine has demonstrated anti-inflammatory properties that may help modulate the neuroinflammatory component of PPD.

Glutamate system modulation: The rapid restoration of glutamatergic signaling may buffer against the mood destabilization that can occur during the dramatic hormonal shifts following delivery.

Pain management: Inadequately managed post-cesarean pain is a risk factor for PPD. Esketamine's analgesic properties may contribute to the preventive effect by reducing pain-related stress and sleep disruption.

Limitations and Caveats

The meta-analysis, while robust, has important limitations:

• Most studies were conducted in China, raising questions about generalizability across different populations and healthcare systems.
• Follow-up duration varied across studies, and longer-term outcomes (beyond three months) are less well-characterized.
• Dosing protocols differed between studies, and the optimal dose for PPD prevention has not been established.
• Risk stratification was not consistently addressed. It remains unclear whether esketamine should be offered to all women undergoing C-section or only those at elevated risk for PPD.

Clinical Implications

If these findings are replicated in larger, more diverse populations, the implications are significant. Cesarean sections account for approximately 30% of deliveries in the United States. A simple addition to the existing anesthetic protocol could potentially prevent postpartum depression in thousands of women each year.

The practical appeal is substantial: no new appointments, no prescription to fill, no daily medication, just a single intravenous dose during a procedure already requiring anesthesia.

The Bottom Line

The 2025 BMC meta-analysis provides compelling evidence that perioperative esketamine can reduce the incidence and severity of postpartum depression following cesarean section. While more research is needed before this becomes standard practice, the data represents a promising shift from treating PPD after it develops to preventing it from occurring in the first place.

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.